![]() “Participants with AD applying 1.5% ruxolitinib cream in this study experienced rapid, substantial improvement in itch, which was sustained and further improved through 28 days of treatment,” study authors wrote. The most common of these were COVID-19, back pain, headache, nasopharyngitis, and upper respiratory tract infection. However, none of these were serious in nature, and none led to participants exiting the study. ![]() With respect to safety endpoints, researchers noted that 15 of 49 participants, or 30.6%, experienced treatment-emergent adverse events. Skin treated with ruxolitinib cream experienced a substantial decrease in TEWL from baseline. Through day 29, the average PP-NRS change from baseline continued to increase, ultimately to –5.7. Researchers had found that the average change in baseline in PP-NRS on day 2 was -3.4. Researchers also collected IGA data on days 1, 8, 15, and 29. Throughout the duration of the study, researchers evaluated several disease-specific factors, including transepidermal water loss (TEWL) on days 1 and 29 and modified PP-NRS (mPP-NRS) on day 1 at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours post drug application. Patients had been instructed to apply the cream to all lesions identified as atopic dermatitis at baseline and to any new lesions. Researchers instructed participants to apply a topical 1.5% ruxolitinib cream on a twice-daily basis at roughly 12 hours apart. Participants were asked to record their PP-NRS scores on a daily basis through day –1 and day 2 through day 29 using an electronic diary. Prospective participants were excluded from participation if they had an unstable course of disease, had used antibiotics within 2 weeks of the start of the run-in period, or other skin conditions that could potentially interfere with study results, to name a few.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |